Journal
EPIGENETICS
Volume 11, Issue 1, Pages 36-48Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/15592294.2015.1132136
Keywords
Epigenome-wide association study; Infinium HumanMethylation450 array; Methyl-Capture Sequencing; DNA methylation; next generation sequencing
Funding
- Strategic Positioning Fund by Agency for Science, Technology and Research (A*STAR), Singapore [SPF002_G00056]
- Singapore Institute for Clinical Sciences (SICS) - A*STAR
Ask authors/readers for more resources
Interindividual variability in the epigenome has gained tremendous attention for its potential in pathophysiological investigation, disease diagnosis, and evaluation of clinical intervention. DNA methylation is the most studied epigenetic mark in epigenome-wide association studies (EWAS) as it can be detected from limited starting material. Infinium 450K methylation array is the most popular platform for high-throughput profiling of this mark in clinical samples, as it is cost-effective and requires small amounts of DNA. However, this method suffers from low genome coverage and errors introduced by probe cross-hybridization. Whole-genome bisulfite sequencing can overcome these limitations but elevates the costs tremendously. Methyl-Capture Sequencing (MC Seq) is an attractive intermediate solution to increase the methylome coverage in large sample sets. Here we first demonstrate that MC Seq can be employed using DNA amounts comparable to the amounts used for Infinium 450K. Second, to provide guidance when choosing between the 2 platforms for EWAS, we evaluate and compare MC Seq and Infinium 450K in terms of coverage, technical variation, and concordance of methylation calls in clinical samples. Last, since the focus in EWAS is to study interindividual variation, we demonstrate the utility of MC Seq in studying interindividual variation in subjects from different ethnicities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available